CAP1 and breast cancer: The prognostic value of CAP1 expression for breast cancer outcomes remained significant among all tumors (OS: HRadj 1.54; 95% CI, 1.11–2.13 and RFS: HRadj 1.47; 95% CI, 1.10–1.96), ER-positive tumors (OS: HRadj 1.69; 95% CI, 1.14–2.50 and RFS: HRadj 1.52; 95% CI, 1.08–2.13), and LN-positive tumors (OS: HRadj 2.00; 95% CI, 1.18–3.45 and RFS: HRadj 2.56; 95% CI, 1.49–4.35) after multivariable analyses adjusted for known confounders (Table 1).